Gå direkt till huvudinnehållet

Trombofili

Senast reviderad:
Sakkunnig:


  1. Federman DG, Kirsner RS. Rewiew article: An update on hypercoagulable disorders. Arch Intern Med 2001; 161: 1051-1056. PubMed  
  2. Moll S. Thrombophilia: clinical-practical aspects. J Thromb Thrombolysis. 2015;39(3):367-378. doi:10.1007/s11239-015-1197-3. PMID: 25724822 PubMed  
  3. Konda, M. Hereditary and Acquired Hypercoagulability. Medscape, last updated Jul 12, 2021 emedicine.medscape.com  
  4. Bucciarelli P, Rosendaal FR, Tripodi A, et al: Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999 Apr; 19(4): 1026-33. PubMed  
  5. Cushman M, O'Meara ES, Folsom AR, Heckbert SR. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood 2009; 114: 2878-83. doi:19617576 www.ncbi.nlm.nih.gov  
  6. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464-474. doi:10.1038/nrcardio.2015.83. PMID: 26076949 PubMed  
  7. Zöller B, García de Frutos P, Hillarp A, Dahlbäck B. Thrombophilia as a multigenic disease. Haematologica. 1999;84(1):59-70. PMID: 10091393 PubMed  
  8. Dautaj A, Krasi G, Bushati V, et al. Hereditary thrombophilia. Acta Biomed. 2019;90(10-S):44-46. Published 2019 Sep 30. doi:10.23750/abm.v90i10-S.8758. PMID: 31577252 PubMed  
  9. Cervera R. Antiphospholipid syndrome. Thromb Res. 2017 ; Mar;151 Suppl 1: S43-S47. pmid:28262233 PubMed  
  10. Rosing J, Middeldorp S, Curvers J, Christella M et al. Low-dose oral contraceptives and aquired resistance to activated protein C: a randomised cross-over study. The Lancet 1999; 354: 2036-40. PMID: 10636369 PubMed  
  11. Valanejad SM, Davis KA. Direct Oral Anticoagulants in Select Patients With Hypercoagulable Disorders. Ann Pharmacother. 2021;55(7):891-901. doi:10.1177/106002802096855. PMID: 33100017 PubMed  
  12. Meijers JCM, Tekelenburg WLH, Bouma BN, Bertina RM, Rosendal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000; 342: 696-701. PubMed  
  13. Campello E, Spiezia L, Adamo A, Simioni P. Thrombophilia, risk factors and prevention. Expert Rev Hematol. 2019;12(3):147-158. doi:10.1080/17474086.2019.1583555. PMID: 30773075 PubMed  
  14. El Hasbani G, Taher AT, Sciascia S, Uthman I. Antiphospholipid syndrome: the need for new international classification criteria. Expert Rev Clin Immunol. 2021;17(4):385-394. doi:10.1080/1744666X.2021.1900733. PMID: 33682558 PubMed  
  15. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x. PMID: 16420554 PubMed  
  16. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005; 293: 2352-61. PMID: 15900005 PubMed  
  17. Connors JM. Thrombophilia Testing and Venous Thrombosis. N Engl J Med. 2017;377(12):1177-1187. doi:10.1056/NEJMra1700365. PMID: 28930509 PubMed  
  18. Lidegaard Ø, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011; 343: d6423. PMID: 22027398 PubMed  
  19. Canonico M, Plu-Bureau G, Lowe GDO, Scarabin P-Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008; 336: 1227-31. www.ncbi.nlm.nih.gov  
  • Anna Nager, docent och specialist i allmänmedicin, Karolinska institutet
  • Terje Johannessen, professor i allmennmedisin, Trondheim